Founder and Chief Executive Officer

Mr. Ben is a farmer and a serial entrepreneur with vast experience in establishing multidisciplinary initiatives. He is the co-founder of Noah's Ark project – the first lyophilized cells from endangered species for preservation and future cloning. Mr. Ben is also the founder and owner of the only private safari in Israel. Prior to founding Amorphical, Mr. Ben was involved with various commercial and agriculture successful projects in Israel and Asia. In 2003, Mr. Ben, as part of one of his agriculture business initiatives of nurturing blue crayfish, was impressed by the prompt skeleton formation after shedding. This observed phenomenon led to research and development of stabilized synthetic amorphous calcium carbonate – the platform technology of Amorphical's dietary supplement products and therapeutic product pipeline.

Vice President of Operations

Mr. Wakshal has 20 years of experience in operations management, product development and innovative development processes for various products and custom-made machinery. Prior to joining Amorphical, Mr. Wakshal served as Director at Uncas Dynamic. His project management experience includes building and up-scaling production plants and developing custom-made turnkey solutions for hi-tech and agricultural companies in Israel and China. Mr. Wakshal holds a Project Management certificate from the Open University of Israel.

Business Development & Global Marketing Director

Mr. Shai Slutzki has more than 10 years of experience in Bio-Tec and High-Tec companies in global marketing, sales and business development positions. Prior of joining Amorphical, Mr. Slutzki worked at Alpha Bio Tec (A global company specializing in bio materials and dental implants) in a senior global marketing position. Mr. Slutzki specializes in building strategies and methods of new market penetration, new product introductions, product launches and distribution management. Mr. Slutzki holds a B.A in Economics & Sociology and an MBA.

Head of Pre-Clinical Research

Dr. Gueta has a proven record in the industrial development of biomaterials, a deep understanding in the medical device development processes and experience managing preclinical studies in various models and applications. Prior to joining Amorphical she served as a product development engineer in CollPlant, an Israeli medical device company. Dr. Gueta holds a Ph.D. in structural biology from the Weizmann Institute of Science, Israel.

Head of Chemical Development

Dr. Zelikovich has more than 15 years of experience as a senior R&D manager in pharma and agro companies. Prior to joining Amorphical, Dr. Zelikovich was with Perrigo API (Chemagis) for 12 years, holding several positions, recently as director of process development. As director of process development, he managed a department responsible for all chemical process development of APIs. Prior to that, he served as head of CMC in biopharmaceutical startup companies, and in the agro chemical industry. Dr.Zelikovich specializes in process optimization, scale up, transfer from lab to industrial production, and IP strategy and process economical evaluations. Dr.Zelikovich holds a PhD from Weizmann Institute in Organic Chemistry, where he is also a lecturer, M.Sc. and B.Sc. in chemistry and biochemistry from the Hebrew University and an MBA from Tel Aviv University. He has more than 15 scientific publications and patents.

Marketing Manager

Ms. Ben David possesses more than 15 years of experience in the consumer and pharmaceutical industries. Prior to joining Amorphical, she held the position of marketing manager for Moraz Skin Care Ltd., a bioherbal cosmetics company, and OTC business unit manager for CTS Pharmaceuticals. Ms. Ben David specializes in health professional communications and B2C (business to consumer) development. Ms. Ben David holds a M.A. degree in political communications from Tel Aviv University, Israel.

Head of Manufacturing

Mr. Nagdiman has 10 years of experience in pharmaceutical and biotech operations, supply chains, and efficacy processes. Prior to joining Amorphical, Mr. Nagdiman worked at Teva Pharmaceutical. This included establishing a new Operational Excellence department, managing the supply of thousands of Teva products and production processes as well as hundreds of employees involved in these areas. Mr. Nagdiman has a deep understanding of the cGMP environment as well as the production regulations and guidelines of the FDA, EMA, Israel’s Ministry of Health, and other regulatory authorities. Mr. Nagdiman holds a B.Sc. in Chemistry and Biology from Tel Aviv University, Tel Aviv, Israel and an MBA degree from the College of Management Academic Studies, Israel.

Associate director of the Chemical Science and Technology Laboratory at SRI International, a pioneer in the development of preceramic polymers—organic-inorganic hybrid materials.

Professor of Physiology and Medicine, Faculty of Medicine at Tel Aviv University. Among other activities, he served as the president of the Israeli Bone, the Mineral Society, and the Israeli Foundation for Osteoporosis and Bone Diseases.

Certified Medical Oncologist. Among other activities, he served as the head of the Lung Cancer Unit at Sheba Medical Center and as the Global Clinical Oncology Platform Leader in Innovative R&D at Teva Pharmaceutical Industries, Ltd.